Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients

International Journal of Biological Markers

Volumn 30, Issue 2, 2015, Pages e190-e199

  Sakurai, Minako ^a   Masuda, Mariko ^a   Miki, Yasuhiro ^a   Hirakawa, Hisashi ^b   Suzuki, Takashi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Breast cancer; ER; HER2; Ki 67; MicroRNA; PR

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA; MICRORNA 148B; MICRORNA 150; MICRORNA 15B; MICRORNA 191; MICRORNA 200C; MICRORNA 21; MICRORNA 25; MICRORNA 96; PROGESTERONE RECEPTOR; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UPREGULATION; VERY ELDERLY; BREAST TUMOR; DEVICES; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; MIDDLE AGED; PATHOLOGY, SURGICAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84934766002     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000141     Document Type: Article

References (51)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
2. Fan M, Krutilina R, Sun J, et al. Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells. J Biol Chem. 2013;288(38):27480-27493.
3. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374.
4. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
6. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with nodenegative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007;8(12):1079-1087.
7. Ishitobi M, Goranova TE, Komoike Y, et al. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol. 2010;40(6):508-512.
8. Wittner BS, Sgroi DC, Ryan PD, et al. Analysis of the Mamma- Print breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008;14:2988-2993.
9. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin- fixed paraffin-embedded samples. RNA. 2007;13(10):1668- 1674.
10. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exper Pathol. 2009;2: 519-527.
11. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519-1524.
12. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93(1):98-104.
13. Masuda M, Miki Y, Hata S, et al. An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med. 2012;10(Suppl 1):S2.
14. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013.
15. Pinto AE, André S, Pereira T, Nóbrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol. 2001;54(7):543-549.
16. Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70(10):4163-4173.
17. Tamaki K, Ishida T, Tamaki N, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2012.
18. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki- 67 in early breast cancer. J Clin Oncol. 2005;23(28):7212-7220.
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747.
20. Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013;9(1):53-59.
21. Elyakim E, Sitbon E, Faerman A, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010;70(20):8077-8087.
22. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR- 130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012; 2(2):e000825.
23. Frampton AE, Krell J, Gall TM, Castellano L, Stebbing J, Jiao LR. miR-15b and miR-17 are tumor-derived plasma microRNAs dysregulated in colorectal neoplasia. Ann Surg. 2014 Mar 18.
24. Schubert M, Spahn M, Kneitz S, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE. 2013;8(6):e65064.
25. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635-647.
26. Iorio M, Croce C. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27:5848-56.
27. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 2011;32(11):1607-1614.
28. Luo Q, Li X, Li J, et al. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013;43(4):1212-1218.
29. Appaiah HN, Goswami CP, Mina LA, et al. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011;13(5):R86.
30. Cochrane DR, Cittelly DM, Howe EN, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010;1(6):306-319.
31. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.
32. Wang X, Cao L, Wang Y, Liu N, You Y. Regulation of let-7 and its target oncogenes [review]. Oncol Lett. 2012;3:955-960.
33. Riaz M, van Jaarsveld MT, Hollestelle A, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013;15(2):R33.
34. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901-906.
35. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67(16):7713-7722.
36. Shibahara Y, Miki Y, Onodera Y, et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol. 2012;227(3):357-366.
37. Sakurai M, Miki Y, Masuda M, et al. LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol. 2012;131:101-106.
38. Barh D, Malhotra R, Ravi B, Sindhurani P. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol. 2010; 17(1):70-80.
39. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA. 2011;108(52):21075-21080.
40. Di Leva G, Piovan C, Gasparini P, et al. Estrogen mediatedactivation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 2013;9(3):e1003311.
41. Klinge CM. MiRNAs and estrogen action. Trends Endocrinol Metab. 2012;23(5):223-233.
42. Maillot G, Lacroix-Triki M, Pierredon S, et al. Widespread estrogen- dependent repression of microRNAs involved in breast tumor cell growth. Cancer Res. 2009;69(21):8332-8340.
43. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65(14):6029-6033.
44. Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010;64:399-408.
45. Han M, Wang Y, Liu M, et al. MiR-21 regulates epithelialmesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012;103(6):1058-1064.
46. Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
47. Wu Q, Jin H, Yang Z, et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 2010;392(3):340-345.
48. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447-1453.
49. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
50. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
51. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8(10):R214.